Obesity medications in development
Open accessAbstract
Introduction: Obesity is compounded by a neurobiology that is resistant to weight loss. Therefore, the development of pharmacotherapies to address the pathology underlying the dysregulation of energy homeostasis is critical.Areas covered: This review examines selected clinical trial evidence for the pharmacologic treatment of obesity and provides an expert opinion on anti-obesity drug development. The article includes the outcomes of anti-obesity medications that have been evaluated in clinical trials but have not yet received approval from the U.S. Food and Drug Administration. The mechanisms of action of glucagon-like peptide-1 agonists and co-agonists, diabetes medications being investigated for weight loss, and medications acting on the central nervous system as well as peripherally are reviewed. A search was conducted on PubMed using the terms ‘Obesity AND Medications’ restricted to clinical trials reported in English. Using similar terms, a search was also conducted on ClinicalTrials.gov.Expert opinion: The goal of anti-obesity therapy is finding compounds that are effective and have minimal side effects. Combining medications targeting more than one of the redundant mechanisms driving obesity increases efficacy. However, targeting peripheral mechanisms to overcome the trickle-down effects of centrally acting drugs may be the key to success in treating obesity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bodyweight is maintained through central nervous system circuitry integrating peripheral metabolic feedback signals of energy surplus or deficit.
“Bodyweight is usually maintained through central nervous system (CNS) circuitry integrating peripheral metabolic feedback signals of either energy surplus or deficit (21, 22).”
From GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918 · see citing works
The Epidemiologic Transition: A Theory of the Epidemiology of Population Change
Omran, A. R. (2005) · Milbank Quarterly · doi:10.1111/j.1468-0009.2005.00398.x · Cited by 3,891 · see citing works
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Self-citationGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · see citing works
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · see citing works
Regulation of short-chain fatty acid production
Macfarlane, S., & Macfarlane, G. T. (2003) · Proceedings of the Nutrition Society · doi:10.1079/pns2002207 · Cited by 1,939 · see citing works
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151 · see citing works
Purushotham, A., Schug, T. T., Xu, Q., Surapureddi, S., Guo, X., & Li, X. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.006 · Cited by 1,112 · see citing works
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · see citing works
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031 · see citing works
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · see citing works
Sirt1 protects against high-fat diet-induced metabolic damage
Pfluger, P. T., Herranz, D., Velasco-Miguel, S., Serrano, M., & Tschöp, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802917105 · Cited by 928 · see citing works
AMPK and SIRT1: a long-standing partnership?
Ruderman, N. B., Julia Xu, X., Nelson, L., Cacicedo, J. M., Saha, A. K., Lan, F., & Ido, Y. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00745.2009 · Cited by 903 · see citing works
Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat
Smith, S. J., Cases, S., Jensen, D. R., Chen, H. C., Sande, E., Tow, B., Sanan, D. A., Raber, J., Eckel, R. H., & Farese, R. V. (2000) · Nature Genetics · doi:10.1038/75651 · Cited by 895 · see citing works
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · see citing works
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · see citing works
AMPK, insulin resistance, and the metabolic syndrome
Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67227 · Cited by 877 · see citing works
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 2× · see citing works
“tide with similar treatment-related adverse events [45].”
BackgroundO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · see citing works
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778 · see citing works
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778 · see citing works
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · see citing works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700 · see citing works
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645 · see citing works
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · see citing works
Sparks, L. M., Xie, H., Koza, R. A., Mynatt, R., Hulver, M. W., Bray, G. A., & Smith, S. R. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1926 · Cited by 629 · see citing works
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · see citing works
Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.001 · Cited by 496 · see citing works
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D. A. H., Khunti, K., & Davies, M. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 496 · see citing works
N-Terminal processing: the methionine aminopeptidase and Nα-acetyl transferase families
Bradshaw, R. A., Brickey, W. W., & Walker, K. W. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01227-4 · Cited by 449 · see citing works
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · see citing works
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417 · see citing works
Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter
Turk, E., Zabel, B., Mundlos, S., Dyer, J., & Wright, E. M. (1991) · Nature · doi:10.1038/350354a0 · Cited by 379 · see citing works
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1× · see citing works
“the weight loss effect permit the activation of GLP1R signaling at lower than maximal doses for enhanced tolerance and efficacy [33].”
BackgroundEffect of Peptide YY3–36 on Food Intake in Humans
Degen, L. P., Oesch, S., Casanova, M., Graf, S., Ketterer, S., Drewe, J., & Beglinger, C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.001 · Cited by 363 · see citing works
Reduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349 · see citing works
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347 · see citing works
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · see citing works
Physiology: Does gut hormone PYY3–36 decrease food intake in rodents?
Tschöp, M., Castañeda, T. R., Joost, H., Thöne-Reineke, C., Ortmann, S., Klaus, S., Hagan, M. M., Chandler, P. C., Oswald, K., Benoit, S. C., et al. (2004) · Nature · doi:10.1038/nature02665 · Cited by 311 · see citing works
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298 · see citing works
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
Kliewer, S. A., & Mangelsdorf, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.004 · Cited by 273 · see citing works
Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes.
Arfin, S. M., Kendall, R. L., Hall, L., Weaver, L. H., Stewart, A., Matthews, B. W., & Bradshaw, R. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7714 · Cited by 257 · see citing works
Charles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity · doi:10.1002/oby.22344 · Cited by 257 · cited 1× · see citing works
“in body weight or glycemic control in obese subjects with type 2 diabetes [56].”
BackgroundAbdul‐Ghani, M. A., DeFronzo, R. A., & Norton, L. (2013) · Diabetes · doi:10.2337/db13-0604 · Cited by 249 · see citing works
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J. E. B., Bush, M., Yang, F., Stewart, M. W., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237 · see citing works
McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 237 · see citing works
Prato, S. D., Nauck, M. A., Durán-Garcia, S., MAFFEI, L. E., Rohwedder, K., Theuerkauf, A., & Parikh, S. J. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12459 · Cited by 232 · see citing works
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V. M., Pérez–Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 232 · see citing works
Intravenous Infusion of Peptide YY(3–36) Potently Inhibits Food Intake in Rats
Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2004) · Endocrinology · doi:10.1210/en.2004-1138 · Cited by 230 · see citing works
Leiter, L. A., Yoon, K., Arias, P., Langslet, G., Xie, J., Balis, D. A., Millington, D., Vercruysse, F., Canovatchel, W. J., & Meininger, G. E. (2014) · Diabetes Care · doi:10.2337/dc13-2762 · Cited by 226 · see citing works
van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 201 · see citing works
Astrup, A., Madsbad, S., Breum, L., Jensen, T. J., Kroustrup, J. P., & Larsen, T. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61525-1 · Cited by 193 · see citing works
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175 · see citing works
Gault, V. A., Irwin, N., Green, B. D., McCluskey, J. T., Greer, B., Bailey, C. J., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2436 · Cited by 172 · see citing works
LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys
Adams, A. C., Halstead, C. A., Hansen, B. C., Irizarry, A. R., Martin, J. A., Myers, S. R., Reynolds, V. L., Smith, H. W., Wroblewski, V. J., & Kharitonenkov, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065763 · Cited by 169 · see citing works
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168 · see citing works
Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164 · see citing works
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158 · see citing works
Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S. L., Suri, V., Qadri, A., Gareski, T., Jones, J. E., Hahm, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.245456 · Cited by 154 · see citing works
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151 · see citing works
Self-citationLong-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys
Véniant, M. M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., Zhou, L., Wada, R., Hecht, R. I., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2012-1211 · Cited by 147 · see citing works
Kim, A. M., Somayaji, V. R., Dong, J. Q., Rolph, T. P., Weng, Y., Chabot, J. R., Gropp, K. E., Talukdar, S., & Calle, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13023 · Cited by 145 · see citing works
TCF1 links GIPR signaling to the control of beta cell function and survival
Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Kolic, J., Baggio, L. L., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.3997 · Cited by 142 · see citing works
Zhao, G., Souers, A. J., Voorbach, M. J., Falls, H. D., Droz, B. A., Brodjian, S. J., Lau, Y. Y., Iyengar, R. R., Gao, J., Judd, A. S., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7013887 · Cited by 139 · see citing works
High-fat diet feeding impairs both the expression and activity of AMPKa in rats’ skeletal muscle
Liu, Y., Wan, Q., Guan, Q., Gao, L., & Zhao, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.068 · Cited by 136 · see citing works
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 129 · see citing works
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 126 · see citing works
Pan, X., & Hussain, M. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.013 · Cited by 111 · see citing works
McCandless, S. E., Yanovski, J. A., Miller, J. E., Fu, C., Bird, L. M., Salehi, P., Chan, C. L., Stafford, D. E. J., Abuzzahab, M. J., Viskochil, D. H., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13021 · Cited by 110 · see citing works
Denison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., AL‐Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12221 · Cited by 104 · see citing works
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
Wilding, J. P. H., Fernando, K., Milne, N., Evans, M., Ali, A., Bain, S. C., Hicks, D., James, J., Newland‐Jones, P., Patel, D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0471-8 · Cited by 97 · see citing works
Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N. J. W., Holst, J. J., & Bloom, S. R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00469 · Cited by 88 · see citing works
Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0180-0 · Cited by 87 · see citing works
Banerjee, J., Bruckbauer, A., & Zemel, M. B. (2016) · Metabolism · doi:10.1016/j.metabol.2016.06.011 · Cited by 85 · see citing works
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81 · see citing works
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81 · see citing works
Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion
Okawa, M., Fujii, K., Ohbuchi, K., Okumoto, M., Aragane, K., Sato, H., Tamai, Y., Seo, T., Itoh, Y., & Yoshimoto, R. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.167 · Cited by 69 · see citing works
Denison, H., Nilsson, C. A. M., Kujacic, M., Löfgren, L., Karlsson, C., Knutsson, M., & Eriksson, J. W. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12002 · Cited by 69 · see citing works
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.07.002 · Cited by 68 · see citing works
Hughes, T. E., Kim, D. D., Marjason, J. K., Proietto, J., Whitehead, J. P., & Vath, J. E. (2013) · Obesity · doi:10.1002/oby.20356 · Cited by 67 · see citing works
Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial
Kim, D. D., Krishnarajah, J., Lillioja, S., de Looze, F., Marjason, J., Proietto, J., Shakib, S., Stuckey, B. G. A., Vath, J. E., & Hughes, T. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12457 · Cited by 62 · see citing works
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B. L., & Probstfield, J. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1600140 · Cited by 62 · see citing works
Salivary PYY: A Putative Bypass to Satiety
Acosta, A. J., Hurtado, M. D., Gorbatyuk, O. S., Sala, M. S. L., Duncan, D. P., Aslanidi, G., Campbell‐Thompson, M., Zhang, L., Herzog, H., Voutetakis, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026137 · Cited by 60 · see citing works
Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease
Astrup, A. V., Meier, D. H., Mikkelsen, B. O., Villumsen, J., & Larsen, T. M. (2008) · Obesity · doi:10.1038/oby.2008.56 · Cited by 57 · see citing works
Hauser, R. A., Salin, L., Juhel, N., & Konyago, V. L. (2006) · Movement Disorders · doi:10.1002/mds.21258 · Cited by 50 · see citing works
Irwin, N., Gault, V. A., Green, B. D., Greer, B., McCluskey, J. T., Harriott, P., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.110 · Cited by 49 · see citing works
Sjödin, A. M., Gasteyger, C., Nielsen, A.-L. H., Raben, A., Mikkelsen, J. D., Jensen, J. K., Meier, D., & Astrup, A. V. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.87 · Cited by 49 · see citing works
Fumagillin Reduces Adipose Tissue Formation in Murine Models of Nutritionally Induced Obesity
Lijnen, H. R., Frederix, L., & HOEF, B. V. (2010) · Obesity · doi:10.1038/oby.2009.503 · Cited by 48 · see citing works
The Effect of Tesofensine on Appetite Sensations
Gilbert, J., Gasteyger, C., Raben, A., Meier, D. H., Astrup, A. V., & Sjödin, A. M. (2011) · Obesity · doi:10.1038/oby.2011.197 · Cited by 36 · see citing works
Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061
Burkey, B. F., Hoglen, N. C., Inskeep, P. B., Wyman, M. A., Hughes, T. E., & Vath, J. E. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.246272 · Cited by 36 · see citing works
Shoemaker, A. H., Proietto, J., Abuzzahab, M. J., Markovic, T., Malloy, J. L., & Kim, D. D. H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12928 · Cited by 32 · see citing works
Lehr, T., Staab, A., Tillmann, C., Nielsen, E. Ø., Trommeshauser, D., Schaefer, H.-G., & Kloft, C. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707539 · Cited by 30 · see citing works
Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin
Streeper, R. S., Koliwad, S. K., Villanueva, C. J., & Farese, R. V. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00621.2005 · Cited by 29 · see citing works
Warder, S. E., Tucker, L. A., McLoughlin, S. M., Strelitzer, T. J., Meuth, J. L., Zhang, Q., Sheppard, G. S., Richardson, P. L., Lesniewski, R., Davidsen, S. K., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr800388p · Cited by 24 · see citing works
Bentzen, B. H., Grunnet, M., Hyveled‐Nielsen, L., Sundgreen, C., Lassen, J. B., & Hansen, H. H. (2013) · Obesity · doi:10.1002/oby.20122 · Cited by 22 · see citing works
Papathanasiou, A. E., Nolen-Doerr, E., Farr, O. M., & Mantzoros, C. S. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0847 · Cited by 20 · see citing works
Nakajima, K., Chatelain, R. E., Clairmont, K. B., Commerford, R., Coppola, G. M., Daniels, T., Forster, C. J., Gilmore, T. A., Gong, Y., Jain, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00173 · Cited by 19 · see citing works
Proietto, J., Malloy, J. L., Zhuang, D., Arya, M., Cohen, N. D., de Looze, F. J., Gilfillan, C. P., Griffin, P. M., Hall, S., Nathow, T., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4677-0 · Cited by 19 · see citing works
Zemel, M. B., Kolterman, O., Rinella, M., Vuppalanchi, R., Flores, O., Barritt, A. S., Siddiqui, M., & Chalasani, N. (2019) · Obesity · doi:10.1002/oby.22346 · Cited by 19 · see citing works
What we need to talk about when we talk about health
Galea, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30867-0 · Cited by 19 · see citing works
Ageing-related receptors resolved
Kuro‐o, M. (2018) · Nature · doi:10.1038/d41586-017-09032-4 · Cited by 18 · see citing works
Elfers, C., & Roth, C. L. (2016) · Endocrinology · doi:10.1210/en.2016-1665 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Obesity: Epidemiology, Pathophysiology, and Therapeutics
Lin, X., & Li, H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.706978 · Cited by 1,404 · see citing works
Adipose tissue, systematic inflammation, and neurodegenerative diseases
Migliolo, L., Boleti, A. P. D. A., Cardoso, P. H. D. O., Frihling, B. E. F., Silva, P. S. E., & de Moraes, L. F. R. N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.343891 · Cited by 90 · see citing works
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69 · see citing works
“Many other drugs are in development, including peptide-YY analogues, incretin coagonists, and other fat-absorption inhibitors [30].”
BackgroundRyan, D. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21033 · Cited by 67 · see citing works
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63 · see citing works
Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse
Song, T., Qin, W., Lai, Z., Li, H., Li, D., Wang, B., Deng, W., Wang, T., Wang, L., & Huang, R. (2023) · Cell Research · doi:10.1038/s41422-023-00800-8 · Cited by 44 · see citing works
GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin
Ouyang, J., Isnard, S., Lin, J., Fombuena, B., Peng, X., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.581839 · Cited by 39 · see citing works
Deng, X., Ye, Z., Cao, H., Bai, Y., Che, Q., Guo, J., & Su, Z. (2020) · Food & Function · doi:10.1039/d0fo01107j · Cited by 38 · see citing works
Appetite control: Hormones or diet strategies?
Freire, R. H., & Alvarez-Leite, J. I. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000675 · Cited by 37 · see citing works
Ryan, D. H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_560 · Cited by 35 · see citing works
Dagpo, T., Nolan, C. J., & Delghingaro‐Augusto, V. (2020) · Cells · doi:10.3390/cells9071596 · Cited by 31 · see citing works
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 31 · see citing works
Obese Animals as Models for Numerous Diseases: Advantages and Applications
Ghanemi, A., Yoshioka, M., & St‐Amand, J. (2021) · Medicina · doi:10.3390/medicina57050399 · Cited by 23 · see citing works
Hao, L., Chen, C., Nie, Y.-H., Kaliannan, K., & Kang, J. X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417261 · Cited by 22 · see citing works
Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems
Fukuyama, K., Motomura, E., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126571 · Cited by 16 · see citing works
Mustafa, Y. F. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100620 · Cited by 10 · see citing works
Choi, Y., Kim, D., Lee, M.-C., Park, S.-G., Lee, J.-W., & Om, A. (2021) · Foods · doi:10.3390/foods10061423 · Cited by 10 · see citing works
Research and prospect of peptides for use in obesity treatment (Review)
Gao, Y., Yuan, X., Zhu, Z., Wang, D., Liu, Q., & Gu, W. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9364 · Cited by 11 · see citing works
Ghanemi, A., Yoshioka, M., & St‐Amand, J. (2021) · Biomolecules · doi:10.3390/biom11121830 · Cited by 9 · see citing works
Qiu, C., Lin, H., Huang, X., & Yu, W. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102984 · Cited by 7 · see citing works
GLP-1 analogues in clinical management of obesity
Agius, R., Matta-Coelho, C., & McGowan, B. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100360 · Cited by 7 · see citing works
Moon, D. (2024) · Biomolecules · doi:10.3390/biom14121572 · Cited by 5 · see citing works
Tuina combined with diet and exercise for simple obesity: A protocol for systematic review.
Chen, L., Cong, D., Wang, G., Sun, J., Ji, Y., Zhong, Z., Liu, T., Liu, J., Chu, Y., & Wu, X. (2022) · PubMed Central · doi:10.1097/md.0000000000028833 · Cited by 3 · see citing works
Qi, S., Li, B.-B., Liu, M., Zhang, Z., Miao, S., & Gong, K. (2022) · Natural Product Research · doi:10.1080/14786419.2022.2103126 · Cited by 3 · see citing works
Metabolic Profiling of Mice with Deletion of the Orphan G Protein-Coupled Receptor, GPR37L1
Mouat, M. A., Wilkins, B. P., Ding, E., Govindaraju, H., Coleman, J. L. J., Graham, R. M., Turner, N. A., & Smith, N. J. (2022) · Cells · doi:10.3390/cells11111814 · Cited by 2 · see citing works
Kumar, J. V., & Pratap, C. G. (2023) · Annals of Phytomedicine An International Journal · doi:10.54085/ap.2023.12.2.87 · Cited by 2 · see citing works
Dong, R., Chen, X., Xue, L., & Qin, P. (2025) · Journal of Acupuncture and Tuina Science · doi:10.1007/s11726-025-1508-y · Cited by 1 · see citing works
Recent Advances and Future Trends in Fermented and Functional Foods
Patra, J. K., Shin, H., & Paramithiotis, S. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-4189-1 · Cited by 1 · see citing works
Atal, A. K., Choudhary, M., & Budhwar, V. (2022) · Journal of Biologically Active Products from Nature · doi:10.1080/22311866.2022.2025901 · Cited by 1 · see citing works
Treating obesity using the combination of metformin and epigallocatechin-3-gallate
Yang, Z., Zhao, X.-Y., Liu, Y., Zhao, B.-C., Luo, Y., Kang, J.-S., & Wang, Q. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00066-3
Park, Y., Seo, D.-W., Gil, T., Kim, H., Jin, J., Cha, Y., & An, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27463 · Cited by 1 · see citing works
Devina, K. E., Indarto, D., Susilawati, T. N., & Wiboworini, B. (2024) · Jurnal Gizi dan Dietetik Indonesia (Indonesian Journal of Nutrition and Dietetics) · doi:10.21927/ijnd.2024.12(2).115-125 · Cited by 1 · see citing works
Obesity as a medical and social problem
Амлаев, К. Р., Atoeva, M., & Жарылкасынова, Г. Ж. (2024) · Vrach · doi:10.29296/25877305-2024-11-06 · Cited by 1 · see citing works
Castillo Sarmiento, C. A., & Rodríguez-Martín, B. (2021) · Ediciones de la Universidad de Castilla-La Mancha eBooks · doi:10.18239/atenea_2021.23.00 · Cited by 1 · see citing works
Estimated Costs of Production Compared with National Prices, for Drugs to Treat Clinical ObesityPreprint
Levi, J., Wang, J., Venter, F., & Hill, A. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4068270 · Cited by 1 · see citing works
El cerebro obeso. Cómo reacciona nuestro cerebro ante el problema de la obesidad
Muñoz‐Rodríguez, J. R. (2021) · Ediciones de la Universidad de Castilla-La Mancha eBooks · doi:10.18239/atenea_2021.23.01
Application in medicine: obesity and satiety control
Kondrashina, A. V., Heffernan, S., O’Brien, N. M., & Giblin, L. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821389-6.00005-4
The pharmacological treatment of obesity: A historical perspective
Cuenca-Ecuador., U. C. D. C., Pacheco, A. V. G., Peláez, C. E. A., & Ortíz, R. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.s3.27
Wang, M., Wang, N., Zhang, H., Liu, J., Chen, X., Feng, Y., Nan, J., & Sun, B. (2022) · Research Square · doi:10.21203/rs.3.rs-2346356/v1
Current and upcoming methods of pharmacotherapy of obesity
BIENIASZ, J., DENDYS, K., KAZZI, M., Puła, M., & WYCHOTA, M. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.04.028
COŞKUN, O. (2024) · doi:10.5152/8516
Bariyatrik Cerrahi Sonrası Sarkopeni: Tanı, Yönetim ve Önleme Stratejileri
Gönenli, M. G. (2024) · doi:10.5152/8522
Adolesanlarda Bariyatrik Cerrahi
Aslan, A., Ebiloğlu, M. F., & Aygen, E. (2024) · doi:10.5152/8509
Polat, S. H. B., & Yumuk, V. (2024) · doi:10.5152/8510
Bariatrik ve Metabolik Cerrahi Genel Prensipler ve Yenilikler II
Taşkın, M., Taşkın, H. E., Zengin, S. Ü., Bedirli, A., Aslan, A., Çalışır, A., Süsleyici, B., Kayaalp, C., Bilgiç, Ç., Büyükkasap, Ç., et al. (2024) · doi:10.5152/8500
Bariatrik ve Metabolik Cerrahi Yapılacak Merkezin Özellikleri ve Gereksinimleri
Bostancı, E. B., & Çolakoğlu, M. K. (2024) · doi:10.5152/8504
Revizyon Cerrahisinde Teknikler ve Adım Adım Revizyon
Omarov, T. I. (2024) · doi:10.5152/8501
Gastrik Bypass Cerrahisi Sonrası Kaçakların Cerrahi Tedavi Seçenekleri
Sobutay, E., BILGI, Ç., & Yavuz, Y. (2024) · doi:10.5152/8521
Obezite Önleyici İlaçların Farmakogenomiği
Duman, B. S. (2024) · doi:10.5152/8520
Süper Obez ve Uzun Dönem Kronik Hastalığı Olan Hastalarda Yönetim
YILMAZ, H., & Çalışır, A. (2024) · doi:10.5152/8512
Obezite ve Metabolik Cerrahide Yeni Teknolojiler
Pehli̇van, M., & ÇETIN, M. F. (2024) · doi:10.5152/8518
Bariatrik ve Metabolik Cerrahide Robotun Yeri
Kaplan, K., & Çetinkünar, S. (2024) · doi:10.5152/8502
Polat, S. H. B., & Yumuk, V. (2024) · doi:10.5152/8523
Kritik Durumdaki Bariyatrik Metabolik Cerrahi Hastasının Yoğun Bakım Takibi
Köksal, G. M. (2024) · doi:10.5152/8514
Sleeve Gastrektomi Kaçakları Sonrası Cerrahi Tedavi
Bılecık, T. (2024) · doi:10.5152/8505
Kompleks Revizyonlarda Robotik Revizyonel Bariatrik Cerrahi
Bedirli, A., Büyükkasap, Ç., & KARABACAK, H. (2024) · doi:10.5152/8517
Yaşlılarda Bariatrik ve Metabolik Cerrahi
Acar, F. (2024) · doi:10.5152/8511
Singh, A., Mansi, Khanna, P., Gupta, D., Singh, S. K., & Khanna, L. (2025) · ChemistrySelect · doi:10.1002/slct.202502210
- Authors
- Rebello, C. J., & Greenway, F. L.
- Affiliations
- Pennington Biomedical Research Center (US)
- Corresponding author
- Greenway, Frank L.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-12-19
- Volume
- 29
- Issue
- 1
- Pages
- 63-71
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- PMC
- PMC6990416
- OpenAlex
- W2996544699
- Cited by
- 62
- References
- 107
- Citations by year
- 2025: 4 · 2024: 23 · 2023: 7 · 2022: 14 · 2021: 9 · 2020: 5
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Civil War Book Review (submittedVersion)
- Funders
- National Institute of General Medical Sciences (U54GM104940)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity, anti-obesity drugs, drug development, GLP-1 receptor agonists, central nervous system drugs, peripheral mechanisms, energy homeostasis, weight loss, adverse drug reactions
- MeSH terms
- Drug Development, Animals, Energy Metabolism, Humans, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
